CSCID (Cosciens Biopharma) Cyclically Adjusted Book per Share: $0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSCID Cosciens Biopharma Inc CSCID
60 GF Score
Price $5.75
GF Value $8.33
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Cosciens Biopharma Cyclically Adjusted Book per Share?

Cosciens Biopharma CSCID 60 Cyclically Adjusted Book per Share is $0.00 as of Mar. 2026. GuruFocus rates CSCID with a GF Score™ of 60/100 and a GF Value™ of $8.33 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Cosciens Biopharma's adjusted book value per share for the three months ended in Mar. 2026 was $0.000. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Cosciens Biopharma's average Cyclically Adjusted Book Growth Rate was 1.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 9.50% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 16.30% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 36.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Cosciens Biopharma was 151.90% per year. The lowest was 9.50% per year. And the median was 47.70% per year.

As of today (2026-07-19), Cosciens Biopharma's current stock price is $5.75. Cosciens Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $0.00. Cosciens Biopharma's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Cosciens Biopharma was 131.74. The lowest was 0.08. And the median was 3.13.


Cosciens Biopharma  (OTCPK:CSCID) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Cosciens Biopharma was 131.74. The lowest was 0.08. And the median was 3.13.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Cosciens Biopharma Cyclically Adjusted Book per Share Related Terms


Cosciens Biopharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Cosciens Biopharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosciens Biopharma Cyclically Adjusted Book per Share Chart

Cosciens Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.10 26.22 33.15 29.77 30.60

Cosciens Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.72 31.37 28.87 30.60 0.00

CSCID vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Cosciens Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosciens Biopharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's Cyclically Adjusted PB Ratio falls into.


CSCID
60GF Score
Cosciens Biopharma Inc CSCID
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cosciens Biopharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cosciens Biopharma's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/132.2623*132.2623
=0.000

Current CPI (Mar. 2026) = 132.2623.

Cosciens Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201606 16.960 102.002 21.992
201609 27.764 101.765 36.085
201612 28.295 101.449 36.889
201703 29.309 102.634 37.770
201706 30.695 103.029 39.404
201709 32.712 103.345 41.865
201712 30.182 103.345 38.627
201803 29.146 105.004 36.712
201806 28.468 105.557 35.670
201809 29.010 105.636 36.322
201812 28.125 105.399 35.293
201903 28.026 106.979 34.650
201906 27.840 107.690 34.192
201909 27.482 107.611 33.777
201912 28.094 107.769 34.479
202003 27.157 107.927 33.280
202006 29.507 108.401 36.002
202009 30.363 108.164 37.128
202012 31.201 108.559 38.013
202103 32.221 110.298 38.638
202106 33.704 111.720 39.901
202109 33.897 112.905 39.709
202112 35.583 113.774 41.365
202203 38.291 117.646 43.048
202206 39.127 120.806 42.838
202209 37.888 120.648 41.535
202212 38.685 120.964 42.298
202303 38.455 122.702 41.451
202306 37.906 124.203 40.366
202309 35.784 125.230 37.793
202312 34.148 125.072 36.111
202403 31.219 126.258 32.704
202406 25.688 127.522 26.643
202409 19.226 127.285 19.978
202412 12.570 127.364 13.053
202503 9.670 129.181 9.901
202506 6.708 129.892 6.830
202509 4.788 130.287 4.861
202512 3.621 130.366 3.674
202603 0.000 132.262 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $0.00 mean?
Cosciens Biopharma (CSCID) has a Cyclically Adjusted Book per Share of $0.00 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Cosciens Biopharma and its competitors.
Is Cosciens Biopharma's Cyclically Adjusted Book per Share too high?
Cosciens Biopharma's current Cyclically Adjusted Book per Share is $0.00. Overall, Cosciens Biopharma has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Cosciens Biopharma's Cyclically Adjusted Book per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Cosciens Biopharma and its competitors. Cosciens Biopharma's current Cyclically Adjusted Book per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCID) is currently considered Possible Value Trap. The stock's GF Value™ is $8.33, compared to a current price of $5.75 — trading 31% below its estimated fair value. The current Cyclically Adjusted Book per Share is $0.00. Cosciens Biopharma's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Cosciens Biopharma (CSCID), the current Cyclically Adjusted Book per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosciens Biopharma (CSCID) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued. The current stock price of $5.75 is trading 31% below its estimated GF Value™ of $8.33. GuruFocus considers Cosciens Biopharma to be Possible Value Trap.

Key valuation signals for CSCID:

  • Cyclically Adjusted Book per Share: $0.00
  • GF Value™: $8.33 vs. price of $5.75 (31% below fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the CSCID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cosciens Biopharma Business Description

Other Exchanges ET8:GermanyCSCI:Canada
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
60GF Score

Get the complete analysis for CSCID

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.75
Price
$8.33
GF Value